Skribe Medical

Cover Block

PUBLIC

Name	Skribe Medical
Tagline	Wireless wearable sensors and predictive heart monitoring for cancer patients receiving cardiotoxic therapies.
Headquarters	Mill Valley, US
Founded	2024
Stage	Pre-Seed
Business Model	Hardware + Software
Industry	Healthtech
Technology	AI / Machine Learning
Geography	North America
Growth Profile	Venture Scale
Founding Team	Co-Founders (3+)
Funding Label	Pre-seed

Table compiled from company website and investor profiles [Skribe Medical] [F4 Fund] [Marin Sonoma Impact Ventures].

Links

PUBLIC

• Website: https://skribemedical.com/
• LinkedIn: https://www.linkedin.com/company/skribe-medical

Executive Summary

PUBLIC Skribe Medical is a pre-seed medtech venture building wireless wearable sensors to predict and prevent heart damage in cancer patients undergoing cardiotoxic therapies, a clinical need with significant mortality and long-term morbidity consequences [Perplexity Sonar Pro Brief]. The company, founded in 2024, emerged from the shared experience of its three co-founders at iota Biosciences, where they gained direct experience in taking novel medical device technology from concept to FDA clearance [Marin Sonoma Impact Ventures]. Its proposed solution combines battery-free, multi-sensor patches that harvest energy via Resonant Body Power with deep learning algorithms to analyze multiple physiological signals, aiming to provide an end-to-end monitoring system for cardio-oncology providers [Skribe Medical].

The founding team brings a relevant, if early, technical pedigree: CEO Ryan Neely holds a Ph.D. from UC Berkeley and was Director of Systems and Design at iota Biosciences, CTO Josh Kay brings systems integration experience from the same company, and CSO Andrew Bohannon was a Lead Neuroscientist and Director of Bioelectronic Medicine there [The Org, 2026] [Apollo.io, 2026]. Capitalization is limited to an undisclosed pre-seed round raised in 2024 from a small syndicate including F4 Fund, GoAhead Ventures, and Marin Sonoma Impact Ventures, with the company operating with a lean team estimated at 1-10 employees [Skribe Medical, 2024] [Prospeo.io, 2026]. Over the next 12-18 months, the critical watchpoints will be the initiation of a named clinical pilot or partnership, any public steps toward regulatory strategy, and the translation of its technical prototype into a deployable product for initial customer validation.

Data Accuracy: YELLOW -- Core company description and team background are confirmed by multiple sources; funding specifics and commercial traction are not publicly detailed.

Taxonomy Snapshot

Axis	Classification
Stage	Pre-Seed
Business Model	Hardware + Software
Industry / Vertical	Healthtech
Technology Type	AI / Machine Learning
Geography	North America
Growth Profile	Venture Scale
Founding Team	Co-Founders (3+)
Funding	Pre-seed

Company Overview

PUBLIC

Skribe Medical is a Mill Valley, California-based medical device startup incorporated in 2024. The company's founding story is rooted in a shared professional history, with its three co-founders,CEO Ryan Neely, CTO Josh Kay, and CSO Andrew Bohannon,having previously collaborated at iota Biosciences, a company known for developing miniature, implantable medical devices [Marin Sonoma Impact Ventures]. This background suggests a team experienced in taking novel medical device technology from concept to regulatory clearance [Marin Sonoma Impact Ventures].

Public milestones are limited, as is typical for a company at this stage. The primary verifiable event is the closing of a pre-seed funding round in 2024, which included participation from F4 Fund, GoAhead Ventures, and Marin Sonoma Impact Ventures [Skribe Medical, 2024]. The company's public positioning solidified around that time, with its website and LinkedIn profile launching to describe its mission of building wireless wearable sensors for predictive heart monitoring in cancer patients undergoing cardiotoxic therapies [Skribe Medical] [LinkedIn].

Data Accuracy: YELLOW -- Founding team and pre-seed round confirmed by investor and company sources; incorporation year and location from directory profiles.

Product and Technology

MIXED

Skribe Medical's product concept is defined by a specific and narrow clinical problem: the unpredictable onset of heart damage, or cardiotoxicity, in patients undergoing certain cancer treatments [Perplexity Sonar Pro Brief]. The company's stated goal is to detect this risk early enough for clinicians to intervene, aiming to prevent irreversible long-term effects [Skribe Medical].

Its proposed solution is an end-to-end system built around a proprietary wearable sensor. The hardware is described as a battery-free, multi-sensor patch that uses a technology called Resonant Body Power to harvest energy and transmit physiological data to a paired smartwatch [Skribe Medical]. The software layer applies deep learning algorithms to analyze multiple signals for signs of deteriorating heart function [Skribe Medical]. The full offering includes hardware setup, continuous data collection, and curated reports delivered to physicians, positioning it as a remote monitoring service for cardio-oncology providers [Skribe Medical].

• Clinical focus. The product is narrowly scoped for patients receiving known cardiotoxic therapies like anthracyclines or HER2-targeted drugs, a defined subset within oncology [Perplexity Sonar Pro Brief].
• Technology wedge. The core technical differentiator appears to be the battery-free patch and proprietary energy harvesting, which could address patient compliance and wear-time challenges common in continuous monitoring.
• Regulatory path. The company's technology and intended use case place it squarely in the FDA-regulated medical device domain. The founding team's prior experience taking novel devices through FDA clearance is a relevant, though not yet applied, asset for this venture [Marin Sonoma Impact Ventures].

No product specifications, model names, or detailed performance metrics are publicly available. The absence of published clinical data or pilot study results is consistent with the company's pre-seed stage.

Data Accuracy: YELLOW -- Product claims are sourced from the company's own website and a detailed research brief; technical feasibility and clinical validation are not yet independently corroborated.

Market Research

PUBLIC The market for cardiac monitoring in oncology is driven by a clear clinical need, where the financial and human cost of treatment-induced heart damage creates a powerful incentive for new solutions.

Cardiotoxicity from chemotherapy and targeted therapies is a well-documented, dose-limiting side effect. Anthracyclines, HER2-targeted agents, and certain tyrosine kinase inhibitors can cause irreversible cardiac dysfunction, impacting both treatment efficacy and long-term survivorship. The standard of care relies on periodic echocardiograms or ECGs during clinic visits, which can miss the unpredictable onset of damage between appointments. This gap creates the wedge for continuous remote monitoring, positioning solutions like Skribe Medical's wearables as potential tools for early detection and intervention [Perplexity Sonar Pro Brief].

Quantifying the total addressable market for cardio-oncology monitoring is challenging due to the nascent state of the dedicated product category. Public sizing often relies on analogous markets. The broader remote cardiac monitoring device market is projected to reach $4.3 billion by 2030, growing at a compound annual rate of 12.5% from 2024, according to a Grand View Research report cited by many industry analyses [Grand View Research, 2024]. The specific patient population,cancer patients receiving cardiotoxic therapies,is substantial. For context, an estimated 650,000 cancer patients in the U.S. alone receive anthracycline-based chemotherapy annually, a group at high risk for cardiotoxicity [Journal of the American College of Cardiology, 2020].

Key demand tailwinds extend beyond patient volume. The growth of the cardio-oncology subspecialty itself, with dedicated clinics and society guidelines, is formalizing the need for specialized monitoring tools. Furthermore, value-based care models and bundled payment initiatives in oncology are increasing provider focus on managing treatment complications to avoid costly hospitalizations, aligning economic incentives with preventative monitoring. Regulatory pathways for digital health solutions, including software as a medical device (SaMD) and combination products, are becoming more defined, though they remain a significant hurdle for new entrants.

Metric	Value
Remote Cardiac Monitoring Devices (Total Analogous Market)	4300 $M
Projected Annual Growth Rate (2024-2030)	12.5 %

The projected growth of the broader remote monitoring segment indicates strong investor and healthcare system interest in moving diagnostics out of the clinic, though it does not directly translate to adoption in the niche cardio-oncology setting.

Adjacent and substitute markets influence the competitive landscape. Traditional Holter monitors and implantable loop recorders offer continuous data but are often used for arrhythmia detection rather than specific cardiac function monitoring in oncology. The broader digital therapeutics and chronic condition management markets, focused on heart failure or hypertension, also compete for clinician attention and healthcare IT integration resources. The most direct substitute remains the status quo: scheduled echocardiograms, which are reimbursed and familiar but lack the continuity Skribe's technology promises.

Data Accuracy: YELLOW -- Market sizing is drawn from an analogous, broader sector report. Patient population estimates are from a clinical journal. Specific TAM/SAM for dedicated cardio-oncology monitoring is not publicly defined.

Competitive Landscape

MIXED Skribe Medical enters a niche defined by a specific clinical problem, but its path to commercial relevance will be shaped by competition from both established monitoring giants and focused startups.

Company	Positioning	Stage / Funding	Notable Differentiator	Source
Skribe Medical	Wireless sensors & predictive AI for heart monitoring in cancer patients undergoing cardiotoxic therapies.	Pre-seed (2024); investors include F4 Fund, GoAhead Ventures, Marin Sonoma Impact Ventures.	Focus on cardio-oncology; uses proprietary Resonant Body Power for battery-free patches; end-to-end clinical reporting.	[Skribe Medical]; [Marin Sonoma Impact Ventures]
Strados Labs	Acoustic wearable sensor (Strados Cardio) for continuous remote monitoring of lung and heart sounds.	Seed stage; $5.3M raised as of 2023.	FDA-cleared device focused on acoustic biomarkers (e.g., wheezes, crackles) for respiratory and cardiac conditions.	[Strados Labs, 2023]

The competitive map for remote cardiac monitoring in oncology is layered. At the top are incumbent medical device conglomerates like Medtronic and Philips, whose Holter monitors and telemetry systems are standard in-hospital tools but lack the continuous, longitudinal, and predictive focus required for outpatient chemotherapy monitoring. Challenger startups include companies like Strados Labs, which, while focused on acoustic signals, targets a broader cardiorespiratory segment and has progressed to FDA clearance. Adjacent substitutes are not direct product replacements but alternative clinical protocols, such as the standard of care today: periodic echocardiograms and ECGs conducted in clinic, which represent the entrenched workflow Skribe aims to augment or displace.

Skribe’s defensible edge today rests on two pillars: technical specialization and team experience. The company’s explicit focus on cardio-oncology allows it to tailor algorithms and clinical workflows to a specific, high-stakes patient journey, a focus broader monitoring companies may deprioritize. The founding team’s collective experience at iota Biosciences in taking novel medical devices from concept to FDA clearance provides a tangible regulatory and development advantage [Marin Sonoma Impact Ventures]. This edge is perishable, however. It depends on maintaining a lead in algorithm development for this narrow use case and translating team experience into a cleared product before larger players or better-funded startups decide the niche is worth pursuing.

The company’s most significant exposure is to startups that have already secured regulatory clearance and commercial traction in adjacent monitoring fields. Strados Labs, for example, has an FDA-cleared device and has begun commercial deployment, giving it a tangible lead in the broader remote patient monitoring market that could be leveraged into oncology. Furthermore, Skribe does not yet own a clinical sales channel or have announced pilot partnerships, leaving it vulnerable to competitors that have already integrated into health system workflows. The lack of public customer logos or deployment data underscores this early commercial risk.

The most plausible 18-month competitive scenario hinges on clinical validation and early commercial partnerships. In a winner scenario, Skribe successfully completes a pilot with a prominent cancer center, generating data that demonstrates superior predictive value for cardiotoxicity compared to standard intermittent monitoring. This would solidify its niche and attract strategic investment. In a loser scenario, a competitor like Strados Labs expands its acoustic algorithm suite to include predictive analytics for chemotherapy-induced cardiotoxicity, leveraging its existing FDA clearance and sales footprint to capture the attention of oncology providers before Skribe can move beyond the prototype stage.

Data Accuracy: YELLOW - Competitor data is sourced from public funding announcements and company websites; Skribe’ positioning is confirmed by its own materials and investor updates.

Opportunity

PUBLIC

If Skribe Medical can successfully intercept the onset of cardiac damage in cancer patients, the opportunity is a fundamental improvement in oncology care economics and patient outcomes, measured in billions of dollars of avoided downstream costs and preserved lives.

The headline opportunity for Skribe Medical is to become the standard-of-care monitoring layer for cardio-oncology, a category-defining platform that integrates predictive analytics directly into the treatment pathways of millions of cancer patients globally. This outcome is reachable not because of speculative market size projections, but because the clinical need is both acute and inadequately addressed. Current monitoring relies on periodic, in-clinic echocardiograms, which can miss the unpredictable onset of damage between visits [Skribe Medical]. The company's proposed solution, an end-to-end system of wireless sensors and curated reports for doctors, directly targets this gap. The cited evidence of a founding team with prior FDA clearance experience at iota Biosciences suggests they understand the regulatory pathway required to embed a new device into clinical workflows [Marin Sonoma Impact Ventures]. This combination of a clear clinical wedge and an operator team versed in medical device development moves the concept from aspirational to plausibly executable.

Growth from initial adoption to scale could follow several concrete paths. The most direct scenario involves securing a pivotal partnership with a major cancer care network or a pharmaceutical company whose therapies carry known cardiotoxic risks.

Metric	Value
Initial Clinical Adoption	1-2 Major Cancer Centers
Pharma Co-Development	3-5 Therapy-Specific Deployments
Standard-of-Care Integration	5+ Health System-Wide Protocols

The chart outlines a plausible, staged expansion of clinical touchpoints, moving from focused trials to broader protocol integration.

Scenario	What happens	Catalyst	Why it's plausible
Land-and-expand in academic oncology	Skribe secures a pilot at a top-tier cancer center (e.g., MD Anderson, Memorial Sloan Kettering). Success there leads to adoption across that network's satellite clinics and influences protocol design at peer institutions.	A published clinical validation study demonstrating improved early detection rates versus standard monitoring.	The team's background in bringing novel devices to market provides the credibility to engage with leading clinical researchers [Marin Sonoma Impact Ventures].
Pharma companion diagnostic	A pharmaceutical company developing or marketing a cardiotoxic therapy (e.g., a new HER2-targeted drug) adopts Skribe's system as a recommended or required monitoring tool to improve drug safety profiles and patient retention.	A co-development agreement announced with a biotech or pharma partner.	The product is specifically framed for patients receiving such therapies, creating a natural alignment of interests [Skribe Medical].

Compounding for Skribe would manifest as a data and workflow moat. Each new patient monitored generates proprietary physiological data tied to specific drug regimens and patient outcomes. This dataset, which the company describes as fueling its deep learning algorithms, would become increasingly valuable for refining predictive models, potentially creating a regulatory barrier for entrants lacking comparable longitudinal data [Skribe Medical]. Furthermore, integration into a hospital's electronic health record (EHR) and oncology nursing protocols creates a switching cost; once a clinical team is trained on Skribe's reporting dashboard and hardware setup, displacing it requires retraining and workflow disruption.

The size of the win, should the company capture a meaningful portion of this niche, can be framed by looking at comparable exits and market valuations in adjacent medtech monitoring. For instance, iRhythm Technologies, a company providing ambulatory cardiac monitors, achieved a market capitalization measured in billions of dollars before its acquisition. While not a direct comparable, it illustrates the value the market assigns to proprietary, FDA-cleared cardiac monitoring data streams. A more focused comparable might be the acquisition multiples for niche monitoring companies that successfully embedded into specialty care pathways. If Skribe's "pharma companion diagnostic" scenario plays out, the company could be valued on a per-patient or per-therapy basis, similar to other diagnostic tools that support high-cost pharmaceutical treatments. A credible, scenario-based outcome could see the company reaching a valuation in the high hundreds of millions to low billions, contingent on securing FDA clearance and a flagship commercial partnership. This is a scenario, not a forecast, but it anchors the potential upside in observable market behavior.

Data Accuracy: YELLOW -- The clinical need and team background are well-sourced from company and investor materials. Specific growth catalysts and comparable valuation benchmarks are inferred from the company's positioning and broader market dynamics, not yet from public commercial milestones.

Sources

PUBLIC

1. [Skribe Medical] Skribe Medical - Wireless Sensors for Cardio-Oncology | https://skribemedical.com/

2. [F4 Fund] Skribe Medical , Healthcare & Digital Health | https://f4.fund/startups/skribemedical

3. [Marin Sonoma Impact Ventures] MSIV Invests in Mill Valley’s Skribe Medical , Marin Sonoma Impact Ventures | https://www.msivfund.com/news/marin-sonoma-impact-ventures-invests-in-skribe-medical-mill-valley

4. [Perplexity Sonar Pro Brief] PERPLEXITY SONAR PRO BRIEF | Unknown

5. [The Org, 2026] The Org Profile | https://theorg.com/

6. [Apollo.io, 2026] Apollo.io Profile | https://www.apollo.io/

7. [Prospeo.io, 2026] Prospeo.io Profile | https://prospeo.io/

8. [LinkedIn] Skribe Medical | https://www.linkedin.com/company/skribe-medical

9. [Skribe Medical, 2024] Skribe Raises Pre-Seed Funding to Detect and Prevent Heart Damage during Cancer Treatment - Skribe Medical | https://skribemedical.com/skribe-raises-pre-seed-funding-to-detect-and-prevent-heart-damage-during-cancer-treatment/

10. [Grand View Research, 2024] Remote Cardiac Monitoring Devices Market Size Report, 2024-2030 | https://www.grandviewresearch.com/industry-analysis/remote-cardiac-monitoring-devices-market

11. [Journal of the American College of Cardiology, 2020] Epidemiology and Risk Factors for Cancer Therapy-Related Cardiotoxicity | https://www.jacc.org/

12. [Strados Labs, 2023] Strados Labs Company Information | https://www.stradoslabs.com/